Orthocell Director Increases Shareholding Through On-Market Purchase

Orthocell Ltd ( (AU:OCC) ) has shared an update.

Orthocell has disclosed a change in director John Van Der Wielen’s interests following an on‑market purchase of 32,500 ordinary shares for $31,337. The transaction increases his direct equity exposure while leaving his 4,000,000 unlisted options, exercisable at $0.40 each by 29 May 2028, and his existing 541,666 ordinary shares unchanged, signalling continued alignment between board and shareholder interests.

The acquisition was executed outside a closed trading period and did not involve any related contracts or derivative arrangements. This incremental share purchase modestly strengthens insider ownership, which may be viewed positively by investors monitoring governance, director confidence and capital markets activity around Orthocell’s regenerative medicine portfolio.

The most recent analyst rating on (AU:OCC) stock is a Sell with a A$0.86 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

More about Orthocell Ltd

Orthocell Limited is an Australian-listed company operating in the medical and biotechnology sector. It focuses on developing and commercialising regenerative medicine technologies and related products, targeting orthopaedic and musculoskeletal conditions in both domestic and international healthcare markets.

Average Trading Volume: 431,776

Technical Sentiment Signal: Hold

Current Market Cap: A$252.3M

For detailed information about OCC stock, go to TipRanks’ Stock Analysis page.